ADAMTS13 activity and the presence of acquired inhibitors in human immunodeficiency virus-related thrombotic thrombocytopenic purpura

Transfusion

Volumn 47, Issue 9, 2007, Pages 1710-1716

  Gunther, Karen ^a,b   Garizio, Dominique ^b   Nesara, Paul ^b  

^a University of the Witwatersrand ^*  (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD4 ANTIGEN; COLLAGEN; FUROSEMIDE; PROTEIN INHIBITOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; BINDING ASSAY; BLOOD CLOTTING; CELL DAMAGE; CELL HETEROGENEITY; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; ENDOTHELIUM; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; OUTCOME ASSESSMENT; PATHOGENESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADAM PROTEINS; HIV; HUMANS; PROTEASE INHIBITORS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 34548135253     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01346.x     Document Type: Article

References (32)

1. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002 347 : 589 600.
2. Amorosi EL, Ultman JE. Thrombotic thrombocytopaenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 1966 45 : 139 59.
3. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopaenic purpura. N Engl J Med 1982 307 : 1432 5.
4. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996 87 : 4223 34.
5. Tsai HM. Physiological cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996 87 : 4235 44.
6. Levy GG, Nicols WC. Lian Ecet al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopaenic purpura. Nature 2001 413 : 488 94.
7. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor cleaving protease in thrombotic thrombocytopaenic purpura and the hemolytic uremic syndrome. N Engl J Med 1998 339 : 1578 84.
8. Tsai HM, Lian EC. Antibodies to von Willebrand factor cleaving protease in acute thrombotic thrombocytopaenic purpura. N Engl J Med 1998 339 : 1585 94.
9. Tsai HM. Is severe ADAMTS13 deficiency specific for thrombotic thrombocytopaenic purpura? Yes. J Thromb Haemost 2003 1 : 625 31.
10. Vesely SK, George JN, Lämmle B, et al. ADAMTS13 activity in thrombotic thrombocytopaenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003 102 : 60 8.
11. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001 98 : 1765 72.
12. Bianchi V, Robles R, Alberio L, Furlan M, Lämmle B. Von Willebrand factor cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severe deficiency is specific for thrombotic thrombocytopaenic purpura. Blood 2002 100 : 710 3.
13. Remuzzi G, Galbusera M, Noris M, et al. Von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopaenic purpura and hemolytic uremic syndrome. Blood 2002 100 : 778 85.
14. Raife TJ, Lentz SR, Atkinson BS, Vesely SK, Hessenr MH. Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor cleaving protease activity. Blood 2002 99 : 437 42.
15. Peyvandi F, Ferrari S, Lavoretano S, Canciani MT, Mannuci PM. Von Willebrand factor cleaving protease (ADAMTS13) and ADAMTS13 neutralising autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol 2004 127 : 433 9.
16. Zheng XL, Kaufman R, Goodnough LT, Sadler J. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura. Blood 2004 103 : 4043 9.
17. Hymes KB, Karpatkin S. Human immunodeficiency virus infection and thrombotic microangiopathy. Semin Hematol 1997 34 : 117 25.
18. Blazes DL, Decke CF. Thrombotic thrombocytopenic purpura in HIV-infected patients. Infect Dis Clin Pract 2004 12 : 99 106.
19. Coppo P, Wolf M, Veyradier A, et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 2005 132 : 66 74.
20. Rick ME, Moll S, Taylor MA, Krizek DM, White GC 2nd., Aronson DL. Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopaenic purpura. Thromb Haemost 2002 88 : 598 604.
21. Tripodi A, Chantarangkul V, Bohm M, et al. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004 2 : 1601 9.
22. Aukrust P, Bjornsen S, Lunden B, et al. Persistently elevated levels of von Willebrand factor antigen in HIV infection downregulation during highly active antiretroviral therapy. Thromb Haemost 2000 84 : 147 61.
23. Mannucci PM, Capoferri C, Canciani MT. Plasma levels of von Willebrand factor regulate ADAMTS13 and its major cleaving protease. Br J Haematol 2004 126 : 213 8.
24. Crawley JT, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005 105 : 1085 93.
25. Gunther K, Dhlamini B. D-dimer levels are markedly raised in HIV-related TTP. AIDS 2007 21 : 1063 4.
26. Miller RF, Sculley M, Cohen H, et al. Thrombotic thrombocytopenic purpura in HIV-infected patients. Int J STD AIDS 2005 16 : 538 42.
27. Sahud M, Claster S, Liu L, Ero M, Harris K, Furlan M. Von Willebrand cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura. Br J Haematol 2002 116 : 909 11.
28. Scheiflinger F, Knöbl P, Trattner B, et al. Non-neutralizing Ig G and Ig M antibodies to Von Willebrand factor cleaving protease (ADAMTS13) in a patient with thrombotic thrombocytopaenic purpura. Blood 2003 102 : 3241 3.
29. Del Arco A, Martinez MA, Pena JM, et al. Thrombotic thrombocytopenic purpura associated with human immunodeficiency virus infection: demonstration of p24 antigen in endothelial cells. Clin Infect Dis 1993 17 : 360 3.
30. Lafrenie RM, Wahl LM, Epstein JS, Hewlett IK, Yamada KM, Dhawan S. HIV-1-Tat modulates the function of monocytes and alters their interaction with microvessel endothelial cells: a mechanism of HIV pathogenesis. J Immunol 1996 156 : 1638 4.
31. Reiter R, Knobl P, Varadi K, Turecek P. Changes in von Willebrand factor cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 2003 101 : 946 8.
32. Novitsky N, Thomson J, Abrahams L, du Toit C, McDonald A. Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy. Br J Haematol 2005 128 : 373 9.